ILB® for Myocardial Infarction

About TikoMed

TikoMed is a clinical-stage biotech advancing ILB®, a novel therapeutic with a unique mechanism aimed at modulating disease pathology by stimulating endogenous repair processes. The company is actively progressing its lead program in Amyotrophic Lateral Sclerosis (ALS) into clinical studies and has outlined plans for other indications like myocardial infarction. With a seasoned management team and strategic academic partnerships, TikoMed operates as a privately held, pre-revenue entity following a build-and-exit strategy for its asset portfolio.

Therapeutic Areas